Pfizer reveals its PD-1 secret
The company talks up sasanlimab, whose subcutaneous delivery might challenge at least some PD-(L)1 laggards.
Pandemic mutations prompt antibody collaborations
A trial testing a combination of Lilly and Vir antibodies is the latest attempt by developers to stay ahead of the virus that causes Covid-19.
Novo takes the plunge in Alzheimer’s
Novo Nordisk is pushing Rybelsus into a pivotal Alzheimer’s trial despite the failure of the Elad study.
Astra aims for “the Trump setting”
Pivotal trials of Astrazeneca's Covid-19 antibody get under way, with hopes that a longer half-life and more convenient dosing will set the project apart.
Scanning the horizon for future Covid-19 treatments
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
